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http:WHAT THIS PAPER ADDS
This study used the newest generation of accelerometers to objectively assess the free-living daily physical
activity level (PA, in metabolic equivalents) of patients with intermittent claudication (IC). Results demonstrate
that less than half of these patients meet the current minimal PA recommendations. The quantiﬁed daily level of
PA in IC is signiﬁcantly lower than in healthy adults. Because a low PA level in IC is considered a strong predictor
of mortality and functional decline, this paper emphasises the need for more awareness to improve physical
exercise in patients with IC.Objectives: Reduced physical activity (PA) is associated with a higher mortality rate and more rapid functional
decline in patients with intermittent claudication (IC). The newest generation of accelerometers can assess both
direction and intensity of activities three-dimensionally and may also adequately calculate energy expenditure in
daily life. The aim of this study was to quantify daily PA level and energy expenditure of newly diagnosed patients
with IC and healthy controls. PA outcomes are compared with contemporary public health physical activity
guidelines.
Methods: Before initiating treatment, 94 patients with newly diagnosed IC and 36 healthy controls were
instructed to wear a tri-axial seismic accelerometer for 1 week. Daily PA levels (in metabolic equivalents, METs)
were compared with the ACSM/AHA public health PA minimum recommendations (64 METs$min$day, in bouts
of 10 minutes). A subgroup analysis assessed the effect of functional impairment on daily PA levels.
Results: Data from 56 IC patients and 27 healthy controls were available for analysis. Patients with IC
demonstrated signiﬁcantly lower mean daily PA levels (SD) than controls (387  198 METs$min vs. 500  156
METs$min, p ¼ .02). This difference was solely attributable to a subgroup of IC patients with the largest
functional impairment (WIQ-score < 0.4). Only 45% of IC patients met the public health physical activity
guidelines compared with 74% of the healthy controls (p ¼ .01).
Conclusions: More than half of patients with IC do not meet recommended standards of PA. Considering the
serious health risks associated with low PA levels, these ﬁndings underscore the need for more awareness to
improve physical exercise in patients with IC.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Intermittent claudication (IC) is closely associated with
cardiovascular and cerebrovascular disease.1e3 Compared
with healthy adults, IC patients are burdened with a low
health-related quality of life and functional impairment
during daily activities.4,5 A reduced exercise capacity and
lower daily free-living physical activity (PA) level are both
strong predictors of long-term mortality. In contrast, higher
PA levels are associated with less functional decline.6e9responding author. J.A.W. Teijink, Catharina Hospital, Department of
r Surgery, P.O. Box 1350, 5602 ZA Eindhoven, The Netherlands.
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//dx.doi.org/10.1016/j.ejvs.2014.03.001The ACSM/AHA have issued recommendations on types
and amounts of PA needed for (older) adults to improve
and maintain health.10 Speciﬁc recommendations are pro-
vided that apply to adults >65 years of age or to adults
aged 50e64 years with chronic conditions or physical
functional limitations.11 All adults are advised to engage in
moderate-intensity aerobic exercise for a minimum of 30
minutes on 5 days a week, or vigorous-intensity aerobic PA
for a minimum of 20 minutes on 3 days a week. Activities
should be performed in bouts of at least 10 minutes.
Combinations of moderate- and vigorous-intensity aerobic
PA can also be performed to meet these recommendations.
Metabolic equivalents (METs) are used by the ACSM/AHA
as a means to express the energy expenditure or energy
costs of physical activities. The total amount of PA is a
function of its intensity, duration, and frequency.
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formed for a particular duration and frequency generate
greater energy expenditure than moderate-intensity activ-
ities (3.0e6.0 METs) of the same duration and frequency.
When combining the recommendations on moderate- and
vigorous-intensity physical activity, the daily minimum goal
of PA should be in the range of 64e107 METs$min.10,11
In the literature, PA is deﬁned and determined in
different ways. Frequently used deﬁnitions of PA are “time
spent in different activities (sedentary/ambulatory), num-
ber of steps, duration of walking events or the score on a
speciﬁc exercise test or questionnaire”.8,12e15 PA objectively
measured by energy expenditure is seldom performed in
patients with IC.15e17 Regularly described methods for PA
measurement are PA questionnaires, pedometers, or ac-
tivity monitors. However, only the last method is found
capable of adequately assessing energy expenditure.18,19
The newest generation of activity monitors is based on
tri-axial accelerometer techniques measuring accelerations
in three dimensions that can be converted to intensities and
METs. In contrast to unilateral accelerometers (or vertical
accelerometers), tri-axial accelerometers also measure ac-
tivities that do not include vertical movement. As such, PA
is determined more precisely as demonstrated with high
correlations between indirect calorimetry and generated
MET output at different walking speeds.18,20,21 To our
knowledge, no studies are available on the use of a tri-axial
accelerometer in patients with IC compared with healthy
adults.
The purpose of this prospective observational study was
to objectively determine the PA using a tri-axial acceler-
ometer in patients with IC and healthy adults. Furthermore,
the number and percentage of participants meeting the
lower limit of the ACSM/AHA recommendations for PA and
public health are determined. It was hypothesised that
healthy adults had a higher PA level and complied more
frequently with these minimum recommendations than IC
patients.MATERIALS AND METHODS
Participant selection
Patients with clinical manifestations of IC were recruited at
the vascular surgery outpatient clinic at the Catharina
Hospital, Eindhoven, and Maxima Medical Center, Veld-
hoven/Eindhoven, The Netherlands. Healthy individuals
recruited from family or friends of health-care workers
served as controls. All subjects gave written informed
consent and all procedures described in this study were
approved by the Medical Ethical Committee, Catharina
Hospital, Eindhoven.Eligibility assessment
IC group. Patients without any previous history of periph-
eral arterial occlusive disease (PAOD) presenting with new-
onset clinical manifestations of IC underwent an anklee
brachial index (ABI) measurement using standardequipment. Patients with values below 0.90 at rest or a
drop in value of more than 0.15 after a standard treadmill
test were considered eligible. Exclusion criteria included
serious cardiopulmonary limitations (NYHA class 3e4),
critical limb ischaemia or previous lower-limb amputation,
use of walking aids, psychiatric instability, or other serious
comorbidity which might possibly limit the patient’s walking
ability.
Control group. Healthy volunteers aged >45 years without
a history of PAOD, or cardiac or pulmonary disease were
included if they were able to walk without any limitations or
walking aids. Participants were excluded if an ABI mea-
surement was below 0.90 at rest or decreased more than
0.15 after a standard treadmill test.
Functional impairment and health-related quality of life
scores
After consenting to the study speciﬁcs, a Dutch validated
version of the Walking Impairment Questionnaire (WIQ),
the 12-item Short Form Physical Functioning Summary (SF-
12 PCS), and the 12-item Short Form Mental Functioning
Summary (SF-12 MCS) were assessed prior to treatment in
the IC patients and in controls.22,23
Evidence-based conservative treatment was subse-
quently started in the IC group. Each patient received car-
diovascular risk management including antiplatelet therapy
and a statin.
Physical activity monitoring
Dynaport tri-axial seismic accelerometer. Both groups of
study participants were asked to wear a tri-axial seismic
accelerometer (Dynaport MoveMonitor, McRoberts B.V.,
The Hague, The Netherlands) during a 1-week time period.
The Dynaport MoveMonitor (size 84 mm  50 m  8 mm;
weight 55 g) contains three orthogonal piezo-capacitive
acceleration sensors, each measuring at a sample rate of
100 Hz. The accelerometer has a direct current response to
the Earth’s gravitational ﬁeld, and uses a seismic or a proof
mass suspended by a spring structure in a case. The case
has a micro USB connection and a rechargeable battery and
stores the raw data on a Micro-SD card. The Dynaport
MoveMonitor is placed in a belt that is strapped around the
waist. It is positioned at the base of the lumbar column just
cranial to the buttocks. The Dynaport technology is vali-
dated for counting steps, detecting time spent in different
activities, activity-related energy expenditure, and assess-
ment of reproducibility.18,21,26e30
Monitoring protocol. All participants were instructed to
correctly wear the Dynaport MoveMonitor for 7 consecu-
tive days. As the device is not waterproof, participants
were asked to take off the device when taking a shower or
a bath. Furthermore, to achieve better compliance, par-
ticipants were instructed not to wear the device during
sleeping.
They were instructed to perform their regular daily ac-
tivities during this week. Supervised exercise therapy (SET)
658 G.J. Lauret et al.was initiated after this 1-week monitoring period in IC
patients. SET was provided by a specialised physical ther-
apist in a community-based setting. According to the
quality standards and guidelines of the Dutch Claudicatio-
Net Network and Royal Dutch Society for Physical Therapy,
the physical therapist assessed the pain-free walking dis-
tance (PFWD) and maximum walking distance (MWD) at
baseline according to a standardised graded treadmill
protocol.24,25Outcomes
Primary outcomes.
- The daily PA level (measured in METs$min)
- The daily PA level performed in bouts of >10 minutes
moderate- or vigorous-intensity PA (measured in
METs$min)
- The number and percentage of participants meeting the
lower limit of the ACSM recommendation for PA and
public health (67$METs$min a day)Secondary outcomes.
- The average daily time spent in different activities
(Lying, Standing, Sitting, Walking, Shufﬂing) and the
time spent not wearing the device
- The average daily number and highest number of steps
walked in one period (top period of steps)
- The average daily time spent in light-, moderate-, or
vigorous-intensity activity. Sedentary activity is activity
with an intensity of <1.5 METs, light activity is activity
with an intensity of 1.5e3 METs, moderate activity is
activity with an intensity of 3e6 METs and vigorous
activity is activity with an intensity of 6e9 METs.Data analysis
Daily checks were made to ensure proper use of the device.
By deﬁnition, the device was worn correctly if it detected at
least 20 steps and if it was “worn” 10 hours and “not
worn” for 5 hours a day. Participants with less than 5 days
of correctly wearing the device were arbitrarily excluded
from analysis. Daily average outcomes were determined for
each participant depending on the number of “correctly
worn days”.
Subgroup analysis. The IC group was divided into two
subgroups according to the WIQ score (<0.4 or 0.4) in
order to evaluate the hypothesis that IC patients with
more functional impairment have a lower daily PA level.
The WIQ score was used because it takes both the pa-
tient’s effort to walk and his perceived impairment into
account, while estimated or treadmill walking distances
do not reﬂect walking distances in daily life.31 A lower
WIQ score reﬂects higher functional impairment. A cut-off
value of 0.4 was arbitrarily chosen to establish even
groups.Statistical analyses. All analyses were performed using IBM
SPSS Statistics Version 21 (SPSS Inc., Chicago, IL, USA).
Categorical variables are presented as frequencies with
percentages. Nominal variables are depicted as the
mean  standard deviation in case of a normal distribution.
Statistical differences between the groups were calculated
with a Pearson chi-square test for categorical variables, an
independent sample t test for continuous variables be-
tween two groups and a one-way between-groups ANOVA
for continuous variables between more than two groups. In
case of signiﬁcant differences between more than two
groups, post hoc Tukey tests were performed to assess a
possible signiﬁcant difference between groups. A p value
<.05 deﬁned statistical signiﬁcance.
Univariate and multivariate linear regression analysis
were used to evaluate which prespeciﬁed variables pre-
dicted the daily level of physical activity. In the univariate
regression analysis, each variable is included in a separate
regression analysis. In the multivariate regression analysis,
all statistically signiﬁcant variables, identiﬁed by the uni-
variate regression analysis, are included in one regression
analysis, using the enter method. Included prespeciﬁed
variables were age, BMI, sex, resting ABI, IC symptoms of
both legs, cardiac history, pulmonary history, WIQ score, SF-
12 PCS score, SF-12 MCS score, and maximal walking dis-
tance measured at baseline. Multivariate linear regression
analysis using the backward elimination method was used
to identify the variables included in the ﬁnal regression
equation. The backward method starts with all the variables
in the equation and in every step variable that does not
have a statistically signiﬁcant inﬂuence is excluded. The
criterion for removal from the regression model was
p > .10. The quality of the regression models was expressed
with the R2 (explained variance) for linear regression
analysis.RESULTS
Group baseline characteristics
A total of 130 participants were considered eligible (IC,
n ¼ 94; controls, n ¼ 36). Analysis of the accelerometer
data demonstrated that 56 IC patients and 27 controls
met all criteria of a correctly worn device. A signiﬁcant
group difference regarding age, number of correctly worn
days, resting ABI, WIQ score, SF-12 PCS score, and MWD
was found between both groups (Table 1).Time spent in different activities or intensity-levels
IC patients spent almost 8.5 hours a day sitting
(508  108 minutes), more than 2.5 hours a day standing
(165  60 minutes), more than 2 hours a day lying
(132  101 minutes), 1 hour a day walking (65  33
minutes), and 21  12 minutes a day shufﬂing (Table 2).
Compared with the control group a signiﬁcant difference
was found in the time spent sitting and “device not worn”.
A signiﬁcant group difference was also found regarding
Table 1. Baseline characteristics.
IC subgroup 1 (n ¼ 30) IC subgroup 2 (n ¼ 26) Control group (n ¼ 27) p-Value
WIQ < 0.4 WIQ  0.4
N (%) Mean SD N (%) Mean SD N (%) Mean SD
Male gender 14 (46.7) e e 16 (61.5) e e 13 (48.1) e e .49a
Both legs symptomatic 18 (60.0) e e 12 (46.2) e e n.a. e e .30a
Pulmonary history 8 (26.7) e e 4 (15.4) e e n.a. e e .31a
Cardiac history 11 (36.7) e e 11 (42.3) e e n.a. e e .67a
Days correct worn device e 5.80 0.61 e 5.80 0.76 e 6.37 0.74 .001b
Age (years) e 69.6 8.8 e 69.4 8.3 e 62.9 9.9 .002b
BMI e 28.0 4.4 e 26.2 3.1 e 26.7 4.2 .23b
Resting ABI e 0.60 0.18 e 0.66 0.18 e 1.10 0.08 <.001b
WIQ score e 0.19 0.12 e 0.62 0.15 e 0.93 0.16 <.001b
SF-12 PCS score e 31.7 8.8 e 40.7 9.8 e 52.0 6.8 <.001b
SF-12 MCS score e 52.6 9.6 e 52.1 7.9 e 52.4 10.1 .98b
PFWD (m) e 155 136 e 233 129 e n.a. n.a. .06c
MWD (m) e 296 225 e 486 274 e n.a. n.a. .008c
Note. ABI ¼ ankle brachial index; BMI ¼ body mass index; WIQ ¼ Walking Impairment Questionnaire; SF-12 PCS score ¼ Short Form-12
Physical Component Summary score; SF-12 MCS ¼ Short Form-12 Mental Component Summary score; PFWD ¼ pain-free walking distance;
MWD ¼ maximum walking distance; n.a. ¼ not applicable.
a Pearson chi-square test.
b One-way between-groups ANOVA.
c Independent sample t-test.
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minutes a day, p ¼ .002).Step analysis
The daily number of steps in the IC subgroups was signiﬁ-
cantly fewer than the control group (IC subgroup 1
4663  3104 vs. IC subgroup 2 5761  2371 vs. Controls
6682  2701, p ¼ .03). The highest number of steps walked
in one period (top period of steps) was also signiﬁcantly
lower in IC patients (IC subgroup 1 1601  1414 vs. IC
subgroup 2 2546  1894 vs. Controls 4584  4680,
p < .001).Daily physical activity level
A statistically signiﬁcant difference (p ¼ .02) in both daily
PA level and daily PA in bouts of >10 minutes of mod-
erate- or vigorous-intensity exercise was found between
the IC subgroups and the control group (Figs. 1 and 2).
Post hoc analyses showed that this difference was solelyTable 2. Average duration of different daily activities and intensity lev
IC group (n ¼ 56)
Mean SD
Lying (hours:min) 2:12 101
Sitting (hours:min) 8:28 108
Standing (hours:min) 2:45 60
Walking (hours:min) 1:05 33
Shufﬂing (hours:min) 0:21 12
Not Worn (hours:min) 9:13 50
Light activity (hours:min) 1:18 33
Moderate activity (hours:min) 1:23 37
Vigorous activity (hours:min) 0:04 8
a Independent sample t test, Light activity ¼ activity with an intensity o
METs, Vigorous activity ¼ activity with an intensity of 6e9 METs.due to a signiﬁcant difference between IC subgroup 1
(WIQ < 0.4) and the control group (p ¼ .018). In contrast,
no signiﬁcant difference in daily PA level was found be-
tween IC subgroup 2 (WIQ  0.4) and the control group
(p ¼ .28).
Analysis of the number of participants achieving the
lower (67 METs$min a day) and upper (107 METs$min a day)
limit of the ACSM minimum recommendations showed a
signiﬁcant difference (lower limit p ¼ .01, higher limit
p ¼ .02) between the IC subgroups and the control group in
favour of the healthy controls (Fig. 3).
Prediction model for daily physical activity level
Univariate regression analysis revealed that age, a previous
history of pulmonary disease, MWD and the WIQ, SF-12
MCS and SF-12 PCS score all independently inﬂuenced the
daily PA level (Table 3). Multivariate regression analysis
including ﬁve variables (age, pulmonary history, SF-12 PFS,
SF-12 MFS, MWD) explained 53% (p < .001) of the variance
in daily PA level:els.
Control group (n ¼ 27) p Valuea
Mean SD
2:10 62 .92
9:20 80 .03
2:33 47 .34
1:16 29 .14
0:26 12 .10
8:16 47 <.001
1:33 55 .13
1:35 29 .11
0:11 10 .002
f 1.5e3 METs, Moderate activity ¼ activity with an intensity of 3e6
Figure 1. Daily physical activity level (mean  SD).
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23  7.65  Age þ 4.73  SF-12 PCS score þ 6.53  SF-12
MCS score þ 0.18 MWD (138.65 if pulmonary history is
present)DISCUSSION
This study hypothesised that IC patients would demonstrate
a lower PA level and would comply less frequently with the
lower limit of the ACSM/AHA recommendations for PA and
public health than healthy adults. In a 2-day assessment of
PA using a vertical accelerometer and a pedometer, one
other study found that the daily PA level of IC patients was
42e45% lower than healthy subjects of similar age.17 Also
using a vertical accelerometer, a second study demon-
strated that patients with PAOD had markedly lower PA
levels than non-PAOD participants (803  364 kcal/wk vs.
1750  1296  kcal/wk).15 Since the ACSM/AHA minimum
recommendations on PA and public health were issued, no
studies describing to what extent IC patients meet these
criteria in relation to healthy adults have been performed.
The present study using the newest generation of tri-axial
accelerometers found that fewer than half of IC patients
meet the ACSM/AHA minimum recommendations while
more than one-quarter of older healthy adults do not meet
these criteria.Figure 2. Daily physical activity level in bouts >10 min of moderate
or vigorous activity (median, IQR).Moreover, the daily level of PA of IC patients
(387  198) is much lower than healthy adults
(500  156). IC patients reporting substantial functional
impairment (WIQ score <0.4) had the lowest mean daily
PA level of all groups. Interestingly, the PA group difference
was solely attributed to this subgroup. Only minor func-
tional impairment in IC patients apparently does not result
in lower daily PA level.
A tri-axial accelerometer allows for separately identifying
various activities such as sitting, standing, lying, or walking.
The present study found signiﬁcant group differences
regarding time of sitting and “not wearing the device”.
Healthy adults appear to sit approximately 1 hour longer
and might sleep less than IC patients. In contrast, walking
time did not differ among groups, although the daily
number of steps and highest number of steps were signif-
icantly lower in the IC group. This difference is possibly
explained by a slower walk pace or cadence associated with
IC. A previous study also suggested that patients with IC
take fewer steps and have a lower daily average cadence
than healthy adults.32
Variables inﬂuencing the daily PA level in IC patients have
hitherto not been identiﬁed.
The present study revealed that age, previous history of
pulmonary disease, MWD and the WIQ, SF-12 MCS and SF-
12 PCS score all independently inﬂuence these levels. Pul-
monary history appeared the strongest factor. However,
patient with serious pulmonary conditions (affecting the
patient’s walking ability) were excluded from this study.
Therefore, the effect of pulmonary history on the daily PA
level in an IC patient is probably underestimated. Patients
with chronic obstructive pulmonary disease are markedly
inactive in daily life compared with healthy adults.33
Therefore, physicians need to realise that patients with IC
and COPD are much less active than IC patients without a
pulmonary history or healthy adults.
A low daily PA level is generally considered a strong
predictor of mortality and functional decline in patients
with IC.6e9 More than light-intensity weekly PA improves 5-
year survival rate signiﬁcantly compared with light-intensity
or no physical activity.7
For this reason, one could argue that the PA level is a
valid outcome parameter in evaluating treatment effects of
any intervention for IC. Current outcome parameters
including maximum- or pain-free walking distances only
describe the patient’s exercise capacity while it does not
reﬂect to what extent this capacity is used. In contrast, daily
PA levels provide objective information on the frequency,
duration, and intensity of exercise. Combined with a func-
tional impairment score such as the WIQ score, physicians
may objectively monitor the patient’s treatment progress.
Future studies should focus on the effects of different
treatment strategies on PA.
A rehabilitation programme such as supervised exercise
therapy (SET) improves walking performance and functional
impairment. Most programmes, in addition to supervised
sessions, promote daily home-based exercise in order to
increase the patient’s daily PA. No studies have
Figure 3. Adherence to ACSM recommendations for physical ac-
tivity and public health.
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Therefore, accelerometer studies before and after different
treatment strategies may shed light on these issues.Study limitations
The present study is limited by the number of excluded
participants. In total, 38 participants in the IC group (40.4%)
and nine controls (25.0%) were excluded because the de-
vice was not correctly worn for 5 days. By deﬁnition, a
correctly worn day was considered a day that the device
was worn for 10 hours, not worn for 5 hours, and with
at least 20 steps. These strict criteria were a priori deter-
mined to prevent bias. For instance, if a participant wore
the device for only 5 hours one day, unrepresentative data
on the overall person’s PA would have been collected. The
high dropout rate may have potentially biased the PA re-
sults, most likely by overestimating the current PA level in ICTable 3. Linear regression models for daily physical activity level (MET
Univariate linear regression
Constanta Bb p Value
Age 1015.33 9.04 <.05
Gender (male) 403.83 29.09 .59
Both legs symptomatic 425.05 70.58 .19
Cardiac history 417.02 75.79 .16
Pulmonary history 432.78 212.51 <.05
BMI 381.92 0.20 .98
Resting ABI 333.86 85.05 .57
WIQ score 300.1 223.83 <.05
SF-12 PCS score 111.22 7.69 <.05
SF-12 MCS score 18.19 7.04 <.05
MWD 282.57 0.27 <.05
a The Constant (in METs$min) of the regression equation is the interc
b The B of the regression equation of the regression equation is the slo
of the association and the inﬂuence of each individual variable (in ME
daily physical activity level.
c Total model: R2 ¼ 0.53, p < .001, Constant ¼ 357.62.
d Total model: R2 ¼ 0.53, p < .001, Constant ¼ 369.23.patients. Lack of motivation or misunderstanding the
monitoring protocol could have led to incorrect use. A
substantial number of participants said they had forgotten
the end date of the monitoring period. In a few instances,
participants fell asleep with the device still strapped to their
waist. In our monitoring protocol, participants were asked
to remove the device before sleeping to improve compli-
ance. If the device was worn during the night, that day was
considered by deﬁnition “not correctly worn”. We are not
sure if compliance could have been higher if participants
wore the device constantly. In future studies, regular check-
ups by phone calls could be employed as a means of
increasing compliance and checking the understanding of
the monitoring protocol. For clinical practice one could
consider a shorter monitoring period, providing results are
summarised in an average daily PA level. However, the ac-
curacy of PA results from a shorter monitoring period
should ﬁrst be validated since these could vary.
Only a few measurement failures with the tri-axial
accelerometer were experienced. The Dynaport Move-
Monitor may fail if the battery is not fully charged or if the
device is worn backwards. The device indicates if it is fully
charged, minimising the chance of human errors. However,
in a handful of cases the device did not measure for 7 days
because the investigators replaced the original SD cards
with new ones. The new SD cards appeared to consume
more battery energy than the original ones. Therefore the
device could only measure for 5 or 6 days. Besides this
error, we did not experience device malfunction. The in-
vestigators explicitly explained how to wear the device to
minimise the chance that participants might wear the de-
vice backwards. This could be explained quite easily since
the device is worn correctly if the word ‘McRoberts’ on the
outside of the device could be read. Therefore this error did
not occur during any of the worn days.
Another study limitation is the lack of an age-matched
control group. Although groups were initially matched fors$min) of participants in the IC group.
Multivariate regressionc Final regressiond
R2 B p Value B p Value
0.15 7.66 .003 7.65 .002
0.01
0.03
0.04
0.20 140.18 0.01 138.65 0.01
0.00
0.01
0.08 63.96 0.55
0.16 5.51 0.04 4.73 .04
0.10 6.57 0.01 6.53 .01
0.13 0.20 0.03 0.18 .04
ept of the regression line on the y-axis.
pe of the regression line and gives information about the direction
Ts$min). The bigger the B, the bigger the inﬂuence per unit on the
662 G.J. Lauret et al.age and sex, a signiﬁcant difference in age was present
between the IC and control group once the IC group drop
out rate appeared high. However, a sensitivity analysis
including healthy adults aged 60 years (n ¼ 14) revealed
no signiﬁcant difference in daily PA level in comparison to
13 other healthy adults aged >60 years (526  160
METs$min vs. 471  151 METs$min, p ¼ .37) although
these groups may have been underpowered.
CONCLUSIONS
More than half of patients with IC do not meet the mini-
mum recommendations for PA and public health. Compared
with healthy adults, they have a signiﬁcantly lower daily PA
level. PA differences are due to an IC subgroup with severe
functional impairments. Because a low PA level is consid-
ered a strong predictor of mortality and functional decline,
all health-care workers should actively encourage physical
activities in IC patients. Future studies should assess the
effects of treatment strategies including supervised exercise
therapy on daily PA levels.
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